Puls, Miriam

[["dc.bibliographiccitation.firstpage","553"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","563"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Viel, Tanja"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Teucher, Nils"],["dc.contributor.author","Hanekop, Gunnar"],["dc.contributor.author","Schoendube, Friedrich"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Seipelt, Ralf G."],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2017-09-07T11:48:50Z"],["dc.date.available","2017-09-07T11:48:50Z"],["dc.date.issued","2012"],["dc.description.abstract","Transcatheter aortic valve implantation (TAVI) has recently developed into an acceptable alternative to conventional surgery in high-risk patients. However, information on the identification of patients gaining most benefit from this procedure is still limited. The aim of this study was to evaluate safety and efficacy of TAVI in different patient cohorts. Between August 2008 and December 2010, 180 high-risk patients underwent TAVI at our institution (97 transapical and 83 transfemoral approaches). Periprocedural complications as well as mortality and incidence of MACCE during follow-up were recorded. Mean age was 82 +/- A 5 years, and mean logistic EuroScore 27 +/- A 14%. In the total cohort, 30-day mortality was 8.9% and 12-month survival (according to Kaplan-Meier-analysis) 72%, with no significant differences between the two approaches. However, a significant difference in survival was obvious after stratification of patients according to logistic EuroScore mortality estimates. Survival proportions at 1 year were 62% in patients with logistic EuroScore > 40%, 71% in patients with EuroScore 20-40% and 80% in octogenarians with EuroScore < 20% (P = 0.009). Furthermore, the observed median event-free survival as an indicator for morbidity ranged between 315 days in the first, 442 days in the second and 710 days in the third group (P = 0.1). TAVI proved to be feasible with reproducible results. However, mortality and rehospitalization rates were considerably high in specific patient cohorts, suggesting that the risk-to-benefit ratio of TAVI should be validated individually. In the present study, octogenarians with logistic EuroScore < 20% could be identified as candidates apparently gaining high benefit from the procedure."],["dc.identifier.doi","10.1007/s00392-012-0426-4"],["dc.identifier.gro","3142507"],["dc.identifier.isi","000305397200006"],["dc.identifier.pmid","22350751"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8091"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8866"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Edwards Lifesciences"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1861-0684"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The risk-to-benefit ratio of transcatheter aortic valve implantation in specific patient cohorts: a single-centre experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1312"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Intensive Care Medicine"],["dc.bibliographiccitation.lastpage","1313"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Hagenah, Gerrit C."],["dc.contributor.author","Klinger, Michael"],["dc.contributor.author","Nagorsnik, Ulf"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Blaschke, Sabine"],["dc.date.accessioned","2018-11-07T08:28:11Z"],["dc.date.available","2018-11-07T08:28:11Z"],["dc.date.issued","2009"],["dc.identifier.doi","10.1007/s00134-009-1398-3"],["dc.identifier.isi","000267220800027"],["dc.identifier.pmid","19169669"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3478"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16365"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0342-4642"],["dc.relation.orgunit","Wirtschaftswissenschaftliche Fakultät"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Acute renal failure due to severe rhabdomyolysis: a rare clinical manifestation of atrial myxoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","45"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cardiovascular Magnetic Resonance"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Lange, Torben"],["dc.contributor.author","Backhaus, Sören J."],["dc.contributor.author","Beuthner, Bo E."],["dc.contributor.author","Topci, Rodi"],["dc.contributor.author","Rigorth, Karl-Rudolf"],["dc.contributor.author","Kowallick, Johannes T."],["dc.contributor.author","Evertz, Ruben"],["dc.contributor.author","Schnelle, Moritz"],["dc.contributor.author","Ravassa, Susana"],["dc.contributor.author","Díez, Javier"],["dc.contributor.author","Toischer, Karl"],["dc.contributor.author","Seidler, Tim"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schuster, Andreas"],["dc.date.accessioned","2022-08-18T12:40:06Z"],["dc.date.available","2022-08-18T12:40:06Z"],["dc.date.issued","2022-07-28"],["dc.date.updated","2022-07-29T12:18:01Z"],["dc.description.abstract","Abstract\n \n Background\n Since cardiovascular magnetic resonance (CMR) imaging allows comprehensive quantification of both myocardial function and structure we aimed to assess myocardial remodeling processes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR).\n \n \n Methods\n CMR imaging was performed in 40 patients with severe AS before and 1 year after TAVR. Image analyses comprised assessments of myocardial volumes, CMR-feature-tracking based atrial and ventricular strain, myocardial T1 mapping, extracellular volume fraction-based calculation of left ventricular (LV) cellular and matrix volumes, as well as ischemic and non-ischemic late gadolinium enhancement analyses. Moreover, biomarkers including NT-proBNP as well as functional and clinical status were documented.\n \n \n Results\n Myocardial function improved 1 year after TAVR: LV ejection fraction (57.9 ± 16.9% to 65.4 ± 14.5%, p = 0.002); LV global longitudinal (− 21.4 ± 8.0% to -25.0 ± 6.4%, p < 0.001) and circumferential strain (− 36.9 ± 14.3% to − 42.6 ± 11.8%, p = 0.001); left atrial reservoir (13.3 ± 6.3% to 17.8 ± 6.7%, p = 0.001), conduit (5.5 ± 3.2% to 8.4 ± 4.6%, p = 0.001) and boosterpump strain (8.2 ± 4.6% to 9.9 ± 4.2%, p = 0.027). This was paralleled by regression of total myocardial volume (90.3 ± 21.0 ml/m2 to 73.5 ± 17.0 ml/m2, p < 0.001) including cellular (55.2 ± 13.2 ml/m2 to 45.3 ± 11.1 ml/m2, p < 0.001) and matrix volumes (20.7 ± 6.1 ml/m2 to 18.8 ± 5.3 ml/m2, p = 0.036). These changes were paralleled by recovery from heart failure (decrease of NYHA class: p < 0.001; declining NT-proBNP levels: 2456 ± 3002 ng/L to 988 ± 1222 ng/L, p = 0.001).\n \n \n Conclusion\n CMR imaging enables comprehensive detection of myocardial remodeling in patients undergoing TAVR. Regression of LV matrix volume as a surrogate for reversible diffuse myocardial fibrosis is accompanied by increase of myocardial function and recovery from heart failure. Further data are required to define the value of these parameters as therapeutic targets for optimized management of TAVR patients.\n Trial registration DRKS, DRKS00024479. Registered 10 December 2021—Retrospectively registered, \n https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024479"],["dc.identifier.citation","Journal of Cardiovascular Magnetic Resonance. 2022 Jul 28;24(1):45"],["dc.identifier.doi","10.1186/s12968-022-00874-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112977"],["dc.language.iso","en"],["dc.publisher","BioMed Central"],["dc.rights.holder","The Author(s)"],["dc.subject","Cardiac magnetic resonance imaging"],["dc.subject","Transcatheter aortic valve replacement"],["dc.subject","Myocardial remodeling"],["dc.subject","Assessment of myocardial function and structure"],["dc.title","Functional and structural reverse myocardial remodeling following transcatheter aortic valve replacement: a prospective cardiovascular magnetic resonance study"],["dc.type","journal_article"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","46"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cardiovascular Magnetic Resonance"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Backhaus, Sören Jan"],["dc.contributor.author","Lange, Torben"],["dc.contributor.author","Beuthner, Bo Eric"],["dc.contributor.author","Topci, Rodi"],["dc.contributor.author","Wang, Xiaoqing"],["dc.contributor.author","Kowallick, Johannes Tammo"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Seidler, Tim"],["dc.contributor.author","Toischer, Karl"],["dc.contributor.author","Zeisberg, Elisabeth M."],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Uecker, Martin"],["dc.contributor.author","Hasenfuß, Gerd P."],["dc.contributor.author","Schuster, Andreas"],["dc.date.accessioned","2021-03-08T07:13:57Z"],["dc.date.available","2021-03-08T07:13:57Z"],["dc.date.issued","2020"],["dc.description.abstract","Myocardial fibrosis is a major determinant of outcome in aortic stenosis (AS). Novel fast real-time (RT) cardiovascular magnetic resonance (CMR) mapping techniques allow comprehensive quantification of fibrosis but have not yet been compared against standard techniques and histology."],["dc.identifier.doi","10.1186/s12968-020-00632-0"],["dc.identifier.pmid","32564773"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80477"],["dc.identifier.url","https://mbexc.uni-goettingen.de/literature/publications/50"],["dc.identifier.url","https://sfb1002.med.uni-goettingen.de/production/literature/publications/359"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","EXC 2067: Multiscale Bioimaging"],["dc.relation","SFB 1002: Modulatorische Einheiten bei Herzinsuffizienz"],["dc.relation","SFB 1002 | D01: Erholung aus der Herzinsuffizienz – Einfluss von Fibrose und Transkriptionssignatur"],["dc.relation.issn","1532-429X"],["dc.relation.workinggroup","RG Hasenfuß"],["dc.relation.workinggroup","RG Uecker"],["dc.relation.workinggroup","RG E. Zeisberg (Kardiales Stroma)"],["dc.relation.workinggroup","RG Backhaus"],["dc.relation.workinggroup","RG Toischer (Kardiales Remodeling)"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Real-time cardiovascular magnetic resonance T1 and extracellular volume fraction mapping for tissue characterisation in aortic stenosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","6653"],["dc.bibliographiccitation.journal","Cases Journal"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Tönges, Lars"],["dc.contributor.author","Pilgram-Pastor, Sara M."],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schmidt, Holger"],["dc.date.accessioned","2019-07-09T11:52:37Z"],["dc.date.available","2019-07-09T11:52:37Z"],["dc.date.issued","2009"],["dc.description.abstract","For prosthetic heart valves the risk of infection is much higher than for native heart valves. During the course of infective endocarditis 20-40% of all patients suffer from cerebrovascular complications such as ischaemic stroke or intracerebral haemorrhage. We present the case of a 57-year-old woman who had undergone surgery to mechanically replace an aortic heart valve 11 months ago and suffered from repeated ischaemic strokes with secondary haemorrhage. The initial antibiotic regimen was ineffective in treating the later diagnosed Staphylococcus aureus infection of the prosthetic valve. Escalation of the antibiotic treatment was not able to halt the clinical course that finally led to the patient's death. The case report emphasizes the importance of early identification of the aetiology of infection in patients with mechanical heart valve replacement. Without rapid and adequate treatment there is a considerable risk for the development of severe neurological sequelae and cardiac failure that can ultimately result in a fatal course of this clinical picture."],["dc.identifier.doi","10.4076/1757-1626-2-6653"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5751"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60238"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/13214 but duplicate"],["dc.rights","CC BY 3.0"],["dc.rights.access","openAccess"],["dc.rights.holder","et al.; licensee BioMed Central Ltd."],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.subject.ddc","610"],["dc.title","Septic embolic encephalitis after Staphylococcus aureus endocarditis of a prosthetic valve in a 57-year-old woman: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2150"],["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Journal of the American College of Cardiology"],["dc.bibliographiccitation.lastpage","2157"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Cuny, Mayumi"],["dc.contributor.author","Berner, Maik"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.date.accessioned","2017-09-07T11:46:04Z"],["dc.date.available","2017-09-07T11:46:04Z"],["dc.date.issued","2010"],["dc.description.abstract","Objectives We assessed the predictive value of heart-type fatty acid-binding protein (H-FABP) in normotensive patients with acute pulmonary embolism (PE). Background Risk stratification of initially normotensive patients with PE on the basis of right ventricular dysfunction or injury remains controversial. Previous studies investigating biomarkers or imaging modalities included unselected patients, some of whom presented with cardiogenic shock. Methods We included 126 consecutive normotensive patients with confirmed PE. Complicated 30-day outcome was defined as death, resuscitation, intubation, or use of catecholamines. Long-term survival was assessed by follow-up clinical examination. Results During the first 30 days, 9 (7%) patients suffered complications. These patients had higher baseline H-FABP values (median, 11.2 ng/ml [interquartile range: 8.0 to 36.8 ng/ml]) compared with patients with an uncomplicated course (3.4 ng/ml [2.1 to 4.9 ng/ml]; p < 0.001). H-FABP values were above the calculated (by receiver operating characteristic curve analysis) cutoff value of 6 ng/ml in 29 patients. Eight (28%) of them suffered complications versus 1 of 97 patients with low H-FABP (negative predictive value, 99%; p < 0.001). By logistic regression, elevated (>= 6 ng/ml) H-FABP was associated with a 36.6-fold increase in the death or complication risk. The combination of H-FABP with tachycardia was a particularly useful prognostic indicator. H-FABP also predicted long-term mortality over 499 (interquartile range: 204 to 1,166) days (hazard ratio: 3.6; 95% confidence interval: 1.6 to 8.2; p = 0.003). Conclusions The H-FABP might be a useful biomarker for risk stratification of normotensive patients with acute PE. (J Am Coll Cardiol 2010;55:2150-7) (C) 2010 by the American College of Cardiology Foundation"],["dc.identifier.doi","10.1016/j.jacc.2009.10.078"],["dc.identifier.gro","3142925"],["dc.identifier.isi","000277303100019"],["dc.identifier.pmid","20447541"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6377"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/383"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: University of Goettingen"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0735-1097"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Elevated Heart-Type Fatty Acid-Binding Protein Levels on Admission Predict an Adverse Outcome in Normotensive Patients With Acute Pulmonary Embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","submitted_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","703"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","712"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Lubos, Edith"],["dc.contributor.author","Boekstegers, Peter"],["dc.contributor.author","von Bardeleben, Ralph Stephan"],["dc.contributor.author","Ouarrak, Taoufik"],["dc.contributor.author","Butter, Christian"],["dc.contributor.author","Zuern, Christine S."],["dc.contributor.author","Bekeredjian, Raffi"],["dc.contributor.author","Sievert, Horst"],["dc.contributor.author","Nickenig, Georg"],["dc.contributor.author","Eggebrecht, Holger"],["dc.contributor.author","Senges, Jochen"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2018-11-07T10:18:07Z"],["dc.date.available","2018-11-07T10:18:07Z"],["dc.date.issued","2016"],["dc.description.abstract","Aims The transcatheter mitral valve interventions (TRAMI) registry was established in order to assess safety and efficacy of catheter-based mitral valve interventional techniques in Germany, and prospectively enrolled 828 MitraClip patients (median age 76 years, median log. EuroSCORE I 20.0%) between August 2010 and July 2013. We present the 1-year outcome in this MitraClip cohort-which is the largest published to date. Methods and results Seven forty-nine patients (90.5%) were available for 1-year follow-up and included in the following analyses. Mortality, major adverse cardiovascular event rates, and New York Heart Association (NYHA) classes were recorded. Predictors of 1-year mortality were identified by multivariate analysis using a Cox regression model with stepwise forward selection. The 1-year mortality was 20.3%. At 1 year, 63.3% of TRAMI patients pertained to NYHA functional classes I or II (compared with 11.0% at baseline), and self-rated health status (on EuroQuol visual analogue scale) also improved significantly by 10 points. Importantly, a significant proportion of patients regained the complete independence in self-care after MitraClip implantation (independence in 74.0 vs. 58.6% at baseline, P = 0.005). Predictors of 1-year mortality were NYHA class IV (hazard ratio, HR 1.62, P = 0.02), anaemia (HR 2.44, P = 0.02), previous aortic valve intervention (HR 2.12, P = 0.002), serum creatinine >= 1.5 mg/dL (HR 1.77, P = 0.002), peripheral artery disease (HR 2.12, P = 0.0003), left ventricular ejection fraction, <30% (HR 1.58, P = 0.01), severe tricuspid regurgitation (HR 1.84, P = 0.003), and procedural failure (defined as operator-reported failure, conversion to surgery, failure of clip placement, or residual post-procedural severe mitral regurgitation) (HR 4.36, P < 0.0001). Conclusions Treatment of significant MR with MitraClip resulted in significant clinical improvements in a high proportion of TRAMI patients after 12 months. In the TRAMI cohort, the failure of procedural success exhibited the highest hazard ratio concerning the prediction of 1-year mortality."],["dc.identifier.doi","10.1093/eurheartj/ehv627"],["dc.identifier.isi","000371251900016"],["dc.identifier.pmid","26614824"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14155"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41363"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1522-9645"],["dc.relation.issn","0195-668X"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]